International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

被引：3623

作者：

Rajkumar, S. Vincent ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

Palumbo, Antonio ^{[3
]}

Blade, Joan ^{[4
]}

Merlini, Giampaolo ^{[5
]}

Mateos, Maria-Victoria ^{[6
]}

Kumar, Shaji ^{[1
]}

Hillengass, Jens ^{[7
]}

Kastritis, Efstathios ^{[2
]}

Richardson, Paul ^{[8
]}

Landgren, Ola ^{[9
]}

Paiva, Bruno ^{[10
]}

Dispenzieri, Angela ^{[1
]}

Weiss, Brendan ^{[11
]}

Leleu, Xavier ^{[12
]}

Zweegman, Sonja ^{[13
]}

Lonial, Sagar ^{[14
]}

Rosinol, Laura ^{[4
]}

Zamagni, Elena ^{[15
]}

Jagannath, Sundar ^{[16
]}

Sezer, Orhan ^{[17
]}

Kristinsson, Sigurdur Y. ^{[18
]}

Caers, Jo ^{[19
]}

Usmani, Saad Z. ^{[20
]}

Lahuerta, Juan Jose ^{[21
]}

Johnsen, Hans Erik ^{[22
]}

Beksac, Meral ^{[23
]}

Cavo, Michele ^{[15
]}

Goldschmidt, Hartmut ^{[7
]}

Terpos, Evangelos ^{[2
]}

Kyle, Robert A. ^{[1
]}

Anderson, Kenneth C. ^{[8
]}

Durie, Brian G. M. ^{[24
]}

San Miguel, Jesus F. ^{[10
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[3] Univ Turin, Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Myeloma Unit, Turin, Italy

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] Univ Hosp Policlin San Matteo, Amyloidosis Ctr, Pavia, Italy

[6] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[7] Heidelberg Univ, Dept Hematol Oncol & Rheumatol, Heidelberg, Germany

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[10] Univ Navarra Clin, Ctr Invest Med Aplicada, Pamplona, Spain

[11] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[12] Univ Hosp Lille, Lille, France

[13] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[14] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[15] Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy

[16] Mt Sinai Canc Inst, New York, NY USA

[17] Mem Hosp, Istanbul, Turkey

[18] Karolinska Univ Hosp, Karolinska Inst, Stockholm, Sweden

[19] CHU Liege, Dept Hematol, Liege, Belgium

[20] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA

[21] Hosp Univ 12 Octubre, Serv Hematol, Madrid, Spain

[22] Aalborg Univ Hosp, Dept Haematol, Aalborg, Denmark

[23] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey

[24] Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA

来源：

LANCET ONCOLOGY | 2014年 / 15卷 / 12期

关键词：

LIGHT-CHAIN RATIO; MULTIPARAMETER FLOW-CYTOMETRY; LENALIDOMIDE PLUS DEXAMETHASONE; UNDETERMINED SIGNIFICANCE MGUS; INDEPENDENT RISK-FACTOR; PLASMA-CELL DISORDERS; MONOCLONAL GAMMOPATHY; IMAGING TECHNIQUES; LONG-TERM; SOLITARY PLASMACYTOMA;

D O I：

10.1016/S1470-2045(14)70442-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.

引用

页码：E538 / E548

页数：11

共 101 条

[1] F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma [J].